Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Why Texas is spending millions to research an illegal psychedelic
4+ week, 2+ day ago (100+ words) Breaking news and analysis on politics, business, world, national news, entertainment and more. In-depth DC, Virginia, Maryland news coverage including traffic, weather, crime, education, restaurant reviews and more. Ibogaine is illegal in the United States, but Texas is on the…...
Health Brief: GLP-1 boom is flooding doctors with drugmaker cash
2+ day, 5+ hour ago (49+ words) washingtonpost.com - Drug companies are spending hundreds of millions of dollars to convince doctors to prescribe GLP-1 drugs - Patient and employer groups are the latest voices pushing for reforms to the law meant to protect people from surprise medical bills...
Why CRISPR Therapeutics Stock Rocked the Market Last Month
4+ day, 7+ hour ago (556+ words) The FDA-approved drug it helped developed saw a nearly 80% sequential rise in sales. It also booked $10 million in upfront payments with a business partner. Pioneering gene-editing company CRISPR Therapeutics(NASDAQ: CRSP) was a well-performing biotech stock in August. Its shares…...
One Swim at a Time: Using Fish to Understand Psychoactive Drugs
5+ day, 17+ hour ago (13+ words) Toledo Blade...
Regulatory data protection will lift India's appeal: Novartis' Judith Love
6+ day, 4+ hour ago (105+ words) On what will make India an attractive investment destination, Love said: ''I think the number one for us to make India attractive is to create an innovative ecosystem.'' Basel-headquartered Novartis, which has the biggest research and development operation in India…...
Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting
2+ week, 3+ day ago (380+ words) Gilead reported big losses last quarter, but this could pave the way for its diversification into oncology. In the meantime, investors remain focused mostly on the main growth driver: HIV prevention medicines. Based on 2027 earnings forecasts, this stock may have…...
ADS-B 'In' Developments Advance Ahead Of Potential Mandates
2+ week, 4+ day ago (54+ words) Aviation Week ADS-B 'In' Developments Advance Ahead Of Potential Mandates American Airlines is undergoing ACSS’ largest installation to date of its SafeRoute+ ADS-B In system. ADS-B 'In' Developments Advance Ahead Of Potential Mandates is part of our Aviation Week & Space…...
Report: Mass. biopharma is bouncing back. But the jobs haven’t yet.
2+ week, 4+ day ago (416+ words) Massachusetts’ biopharma industry is showing signs of a comeback, but its workforce is still feeling the effects of the downturn. Employment in the state’s biopharma sector fell 3.1% in 2025, or about 3,600 jobs, marking the first annual decline in more than two…...
Syngenis banks R&D refund to fuel biotech build-out
2+ week, 5+ day ago (521+ words) August 25, 2026 — 9:05am Australian biotechnology company Syngenis Labs has received a $363,000 research and development tax refund, adding another shot of non-dilutive capital to its genetic medicine ambitions. The refund lands shortly after the company closed an oversubscribed $4 million pre-IPO raise through Euroz…...
Big pharma’s next $10 billion gamble: Ozempic for your brain
2+ week, 5+ day ago (695+ words) August 25, 2026 — 5:00am A new wave of treatments for a rare illness are being touted as the next major breakthrough from the same class of drugs as Ozempic, sparking multibillion-dollar acquisitions from pharmaceutical giants but caution from experts who warn that more…...